From King's College London (R.A.A.K., S.C.W.), Department of Psychological Medicine, Institute of Psychiatry, London, UK; Université Paris Descartes (J.P.L.), Faculté de Pharmacie, Neuropsychopharmacologie des Addictions, CNRS, et Université Paris 7, France; INSERM (J.P.L.), Paris, France; Assistance Publique-Hôpitaux de Paris (J.P.L.), Hôpital Fernand Widal, Service de Psychiatrie, Paris, France.
Address correspondence and reprint requests to Simon Wessely, Institute of Psychiatry, Department of Psychological Medicine, P062, Weston Education Centre, London SE5 9RJ, UK. E-mail: [email protected]
Received for publication March 7, 2007; revision received May 31, 2007.
Richard A. A. Kanaan, MRCPsych, was supported by a Biomedical Ethics Fellowship from the Welcome Trust (079743).
This article is being co-published by Psychosomatic Medicine and the American Psychiatric Association.
